论文部分内容阅读
目的通过对Ⅰ期肺腺癌患者的一系列分子生物学标记物的评估,找出有判断预后价值的分子生物学指标。方法应用免疫组化方法检测68例Ⅰ期肺腺癌术后癌组织中Ki-67、Her-2、P16、p53、VEGF、MMP-9和CD44v6的表达情况。用COX相对危险回归法分析这些因子的表达情况与患者预后的关系。结果多因素分析表明以下分子标记物的表达与患者不良预后有显著相关性:p53(RR=3.228,p=0.010);MMP-9(RR=2.071,p=0.033);VEGF(RR=2.577,p=0.025)。结论p53、VEGF、MMP-9对Ⅰ期肺腺癌患者的预后判断有重要价值,多因子联合检测更有意义。
Objective To evaluate the molecular biomarkers of patients with stage Ⅰ lung adenocarcinoma and to find the molecular biological indicators for judging the prognostic value. Methods The expressions of Ki-67, Her-2, P16, p53, VEGF, MMP-9 and CD44v6 in 68 cases of stage I lung adenocarcinoma were detected by immunohistochemistry. The relative risk of COX regression analysis of the relationship between the expression of these factors and the prognosis of patients. Results Multivariate analysis showed that there was a significant correlation between the following molecular markers and poor prognosis: p53 (RR = 3.228, p = 0.010); MMP-9 p = 0.025). Conclusions The prognostic value of p53, VEGF and MMP-9 in patients with stage I lung adenocarcinoma is of great value. The combination of multiple factors is more meaningful.